Abbott Laboratories (NYSE: ABT) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | S&P 500 | P/E | 33.84 | EPS (ttm) | 3.11 | Insider Own | 0.61% | Shs Outstand | 1.73B | Perf Week | -3.40% |
| Market Cap | 182.09B | Forward P/E | 17.35 | EPS next Y | 6.06 | Insider Trans | -3.67% | Shs Float | 1.72B | Perf Month | -3.12% |
| Enterprise Value | 209.09B | PEG | 3.17 | EPS next Q | 1.43 | Inst Own | 76.44% | Short Float | 1.18% | Perf Quarter | 15.32% |
| Income | 5.42B | P/S | 3.91 | EPS this Y | 77.39% | Inst Trans | 0.00% | Short Ratio | 1.69 | Perf Half Y | -4.81% |
| Sales | 46.59B | P/B | 3.52 | EPS next Y | 9.93% | ROA | 4.97% | Short Interest | 20.38M | Perf YTD | -16.01% |
| Book/sh | 29.91 | P/C | 32.50 | EPS next 5Y | 10.67% | ROE | 10.52% | 52W High | 137.48 -23.46% | Perf Year | -20.40% |
| Cash/sh | 3.24 | P/FCF | 21.49 | EPS past 3/5Y | -1.65% 8.27% | ROIC | 6.07% | 52W Low | 81.97 28.38% | Perf 3Y | 2.31% |
| Dividend Est. | 2.52 (2.39%) | EV/EBITDA | 21.03 | Sales past 3/5Y | 0.51% 5.08% | Gross Margin | 56.80% | Volatility | 2.77% 2.24% | Perf 5Y | -16.73% |
| Dividend TTM | 2.48 (2.36%) | EV/Sales | 4.49 | EPS Y/Y TTM | -59.29% | Oper. Margin | 17.03% | ATR (14) | 2.78 | Perf 10Y | 143.31% |
| Dividend Ex-Date | Jul 15, 2026 | Quick Ratio | 0.97 | Sales Y/Y TTM | 11.05% | Profit Margin | 11.65% | RSI (14) | 40.04 | Recom | 2.22 |
| Dividend Gr. 3/5Y | 7.87% 10.38% | Current Ratio | 1.38 | EPS Q/Q | 3.97% | SMA20 | -5.64% | Beta | 0.57 | Target Price | 123.64 |
| Payout | 78.54% | Debt/Eq | 0.29 | Sales Q/Q | 13.02% | SMA50 | 0.36% | Rel Volume | 0.58 | Prev Close | 105.52 |
| Employees | 115,000 | LT Debt/Eq | 0.22 | Earnings | Oct 21 | SMA200 | -0.80% | Avg Volume | 11.08M | Price | 105.23 |
| IPO Date | Mar 17, 1980 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 2.56% 0.59% | Net Debt/EBITDA | 2.77 | Volume | 6,470,781 | Change | -0.27% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-13-26 | Upgrade | Wolfe Research | Peer Perform → Outperform | $130 |
| Jul-28-26 | Reiterated | UBS | Buy | $115 → $125 |
| Jul-20-26 | Reiterated | Benchmark Co. | Buy | $120 |
| Jul-17-26 | Reiterated | Piper Sandler | Overweight | $115 → $118 |
| Jul-06-26 | Reiterated | Evercore ISI Group | Outperform | $138 → $112 |
| Jun-30-26 | Initiated | Baird | Outperform | $121 |
| Apr-22-26 | Reiterated | Daiwa | $92 | |
| Apr-20-26 | Reiterated | Barclays | Overweight | $142 → $143 |
| Apr-17-26 | Reiterated | UBS | Buy | $132 → $115 |
| Apr-17-26 | Reiterated | Stifel Nicolaus | Buy | $145 → $120 |
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 46,585 | 44,328 | 41,950 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 20,123 | 19,721 | 20,625 | — | — | — | — | — | — | |
| Gross Profit | 26,462 | 24,607 | 21,325 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 13,477 | 12,378 | 11,651 | — | — | — | — | — | — | |
| Research and Development | 3,158 | 2,955 | 2,823 | — | — | — | — | — | — | |
| Other Operating Expense | 1,922 | 1,253 | 0 | — | — | — | — | — | — | |
| Operating Income | 7,932 | 8,048 | 6,825 | — | — | — | — | — | — | |
| Interest Expense | 637 | 341 | 603 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 216 | 759 | 791 | — | — | — | — | — | — | |
| Net Income Before Taxes | 7,511 | 8,466 | 7,013 | — | — | — | — | — | — | |
| Income Taxes | 2,086 | 1,942 | -6,389 | — | — | — | — | — | — | |
| Consolidated Net Income | 5,425 | 6,524 | 13,402 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 5,425 | 6,524 | 13,402 | — | — | — | — | — | — | |
| Net Income | 5,425 | 6,524 | 13,402 | — | — | — | — | — | — | |
| EPS (Recurring) | 3.11 | 3.74 | 7.67 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 3.11 | 3.74 | 7.67 | — | — | — | — | — | — | |
| EPS (Diluted) | 3.11 | 3.72 | 7.64 | — | — | — | — | — | — | |
| EBITDA | 9,943 | 11,553 | 10,834 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 33.84 | 33.68 | 14.80 | — | — | — | — | — | — | |
| Price To Sales Ratio | 3.94 | 4.94 | 4.67 | — | — | — | — | — | — | |
| Gross Margin | 56.80 | 55.51 | 50.83 | — | — | — | — | — | — | |
| Operating Margin | 17.03 | 18.16 | 16.27 | — | — | — | — | — | — | |
| Net Margin | 11.65 | 14.72 | 31.95 | — | — | — | — | — | — | |
| Shares Outstanding | 1,743 | 1,747 | 1,732 | — | — | — | — | — | — | |
| Market Capitalization | 183,416 | 218,882 | 195,907 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| MCCOY JOHN A. JR. | VICE PRESIDENT AND CONTROLLER | Sep 02 '26 | Sale | 109.54 | 27 | 2,958 | 24,549 | Sep 03 |
| Ford Robert B | CHAIRMAN AND CEO | Aug 25 '26 | Sale | 115.85 | 398,832 | 46,204,798 | 306,461 | Aug 27 |
| Ford Robert B | CHAIRMAN AND CEO | Aug 25 '26 | Option Exercise | 54.02 | 398,832 | 21,545,946 | 705,293 | Aug 27 |
| Morrone Louis H. | EXECUTIVE VICE PRESIDENT | Aug 11 '26 | Sale | 109.83 | 5,850 | 642,506 | 70,724 | Aug 13 |
| Stratton John G | Director | May 07 '26 | Buy | 86.82 | 2,000 | 173,640 | 23,319 | Jun 18 |
| STARKS DANIEL J | Director | Apr 27 '26 | Buy | 92.65 | 10,000 | 926,537 | 6,751,103 | Apr 28 |
| Boudreau Philip P | EVP AND CFO | Apr 23 '26 | Buy | 91.50 | 2,200 | 201,300 | 2,200 | Apr 27 |
| Morrone Louis H. | EXECUTIVE VICE PRESIDENT | Mar 02 '26 | Sale | 115.58 | 1,144 | 132,224 | 76,843 | Mar 03 |
| Shroff Eric | Senior Vice President | Mar 02 '26 | Sale | 115.58 | 709 | 81,946 | 39,164 | Mar 03 |
| Cushman Elizabeth C. | EVP, GC AND SECRETARY | Mar 02 '26 | Sale | 115.58 | 263 | 30,398 | 38,573 | Mar 03 |
| MCCOY JOHN A. JR. | VICE PRESIDENT AND CONTROLLER | Mar 02 '26 | Sale | 115.58 | 585 | 67,614 | 24,628 | Mar 03 |
| Salvadori Daniel Gesua Sive | EVP AND GROUP PRESIDENT | Mar 02 '26 | Sale | 115.58 | 885 | 102,288 | 146,377 | Mar 03 |
| Moreland Mary K | EXECUTIVE VICE PRESIDENT | Mar 02 '26 | Sale | 115.58 | 613 | 70,851 | 104,291 | Mar 03 |
| STARKS DANIEL J | Director | Feb 04 '26 | Buy | 108.73 | 10,000 | 1,087,331 | 6,738,817 | Feb 06 |
| Ford Robert B | CHAIRMAN AND CEO | Jan 23 '26 | Buy | 107.13 | 18,800 | 2,013,967 | 216,203 | Jan 26 |